BioStock: Tumorad's potential in transforming cancer care

In an era where cutting-edge science is radically transforming the healthcare landscape, Spago Nanomedical has garnered significant attention with its radionuclide cancer therapy project Tumorad. This initiative aims to provide a ground-breaking alternative in cancer treatment. To learn more about Tumorad’s potential, BioStock reached out to Spago's CEO Mats Hansen for an interview.

Read the interview with Mats Hansen at biostock.se:

Tumorad's potential in transforming cancer care - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/